U.S. Stock Market Performance: U.S. stocks opened higher, with the Nasdaq Composite gaining over 300 points, while the Dow rose 0.41% and the S&P 500 increased by 0.82%. Information technology shares saw a 1.5% jump, but consumer staples stocks fell by 0.3%.
Keurig Dr Pepper's Financial Results: Keurig Dr Pepper Inc. shares surged around 6% after exceeding sales expectations for Q3 2025, reporting a 10.7% year-over-year sales increase and maintaining adjusted earnings per share at 54 cents.
Significant Stock Movements: Sotherly Hotels Inc. shares skyrocketed 137% following an acquisition announcement, while Co-Diagnostics, Inc. and BIO-key International, Inc. also saw substantial gains of 133% and 110%, respectively. Conversely, Intellia Therapeutics, Inc. and Genenta Science S.p.A. experienced significant declines of 42%.
Global Market Overview: European shares were mixed, with the eurozone's STOXX 600 slightly up, while Asian markets closed higher, led by Japan's Nikkei 225 gaining 2.46%. Commodity prices showed a slight decline in oil and gold, while copper rose by 0.8%.
Wall Street analysts forecast CODX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CODX is 1.50 USD with a low forecast of 1.50 USD and a high forecast of 1.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast CODX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CODX is 1.50 USD with a low forecast of 1.50 USD and a high forecast of 1.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 2.360
Low
1.50
Averages
1.50
High
1.50
Current: 2.360
Low
1.50
Averages
1.50
High
1.50
Maxim
Buy
to
Hold
downgrade
2026-01-23
New
Reason
Maxim
Price Target
AI Analysis
2026-01-23
New
downgrade
Buy
to
Hold
Reason
Maxim downgraded Co-Diagnostics to Hold from Buy.
Maxim
Jason McCarthy
Buy
to
Hold
downgrade
2026-01-23
New
Reason
Maxim
Jason McCarthy
Price Target
2026-01-23
New
downgrade
Buy
to
Hold
Reason
As previously reported, Maxim analyst Jason McCarthy downgraded Co-Diagnostics to Hold from Buy. The company received written notice from NASDAQ that it had decided to delist the company's stock due to non-compliance with the minimum bid price requirement, the analyst tells investors in a research note. Delisting does not change the firm's fundamentally positive view regarding the company's prospects, Co-Primer technology, and the commercial potential of the PCR Pro, but to unlock value, Co-Dx will likely need to access capital markets and raise additional capital, which is made considerably more difficult without a major exchange listing, the firm added.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CODX
Unlock Now
Maxim
NULL -> Buy
initiated
$1.50
2025-11-26
Reason
Maxim
Price Target
$1.50
2025-11-26
initiated
NULL -> Buy
Reason
Maxim initiated coverage of Co-Diagnostics with a Buy rating and $1.50 price target.
HC Wainwright & Co.
Yi Chen
Hold
Maintains
$1.5 → $1
2025-03-28
Reason
HC Wainwright & Co.
Yi Chen
Price Target
$1.5 → $1
2025-03-28
Maintains
Hold
Reason
About CODX
Co-Diagnostics, Inc. is a molecular diagnostics company, which develops, manufactures and markets diagnostics technologies. The Company’s technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious disease. Its diagnostics systems enable dependable, low-cost, molecular testing for organisms and genetic diseases by automating or simplifying historically complex procedures in both the development and administration of tests. It is developing a portable diagnostic device and test system designed for point-of-care and at-home use. The system consists of its PCR instrument that it refers to as the Co-Dx PCR Pro instrument, its proprietary diagnostic test cup system and a mobile application to be installed on the user’s mobile device.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
